How to Advocate for Gdm Screening During Prenatal Visits

Understanding the Importance of GDM Screening

Gestational diabetes mellitus (GDM) affects approximately 6–9% of pregnancies in the United States, with rates rising globally as maternal age and obesity prevalence increase. Screening for GDM between 24 and 28 weeks of gestation is a standard recommendation from organizations such as the American College of Obstetricians and Gynecologists (ACOG) and the American Diabetes Association (ADA). Yet, despite clear guidelines, many women miss or delay screening due to lack of awareness, limited access to care, or inadequate provider advocacy. Effective advocacy during prenatal visits can close that gap, ensuring that every pregnant patient receives timely screening, early intervention, and the best possible outcomes for both mother and child.

Advocacy is not merely about recommending a test—it is about empowering patients with knowledge, addressing fears, and creating a clinical environment where shared decision-making thrives. This article outlines evidence-based strategies for clinicians, nurse‑midwives, diabetes educators, and other prenatal care providers to advocate effectively for GDM screening at every opportunity.

Why GDM Screening Matters

Untreated or poorly controlled GDM carries significant short- and long-term risks. In the perinatal period, hyperglycemia drives excess fetal insulin secretion, leading to macrosomia (birth weight > 4,000 g), shoulder dystocia, neonatal hypoglycemia, and increased rates of cesarean delivery. The mother faces higher risks of preeclampsia, polyhydramnios, and future type 2 diabetes—studies show that women with GDM have a seven‑fold higher risk of developing type 2 diabetes later in life. Screening provides a crucial window for lifestyle modifications, glycemic monitoring, and, when necessary, pharmacologic therapy (insulin or metformin) that can normalize outcomes.

Universal screening, as opposed to risk‑factor‑based screening, captures women who would otherwise be missed—up to 50% of GDM cases occur in women with no traditional risk factors. That is why major health authorities recommend a two‑step or one‑step oral glucose tolerance test (OGTT) for all pregnant individuals at 24–28 weeks, with earlier testing for those with high BMI, prior GDM, or a family history of diabetes. The evidence supporting this approach is robust; a 2021 Cochrane review confirmed that treatment of GDM reduces the risk of macrosomia, shoulder dystocia, and preeclampsia without increasing the rate of unnecessary C‑sections.

Links to Authoritative Guidelines

Barriers to GDM Screening

Even when guidelines are clear, screening rates remain suboptimal. Understanding the barriers is the first step to advocacy.

Patient-Side Barriers

Fear of the OGTT: The beverage is often described as “too sweet” or nauseating, and some women worry about vomiting or feeling faint after the drink.
Time constraints: The two‑step test requires a 1‑hour glucose challenge test (GCT) and, if abnormal, a 3‑hour OGTT. Working women may struggle to take additional time off for appointments.
Misinformation: Myths such as “I don’t have diabetes so I can’t get it in pregnancy” or “screening is only for overweight women” persist even in educated populations.
Language and health literacy: Patients with limited English proficiency or low health literacy may not fully understand why the test is done or how to prepare.

Provider-Side Barriers

Time pressure: Prenatal visits are packed; discussing GDM screening can feel like one more task in a 15‑minute encounter.
Assumption of adherence: Some providers assume that patients who screen positive will simply “eat better” and skip offering medication or referral to a diabetes educator.
Outdated protocols: Not all practices have updated to current guidelines; some still use risk‑based screening despite evidence favoring universal screening.

Advocacy directly addresses each of these barriers through proactive education, anticipatory guidance, and system-level changes that make screening easier for everyone.

Advocacy Strategies for the Prenatal Visit

The prenatal visit is the primary touchpoint for GDM advocacy. Below are concrete, evidence‑informed strategies organized by the timing of the visit.

First Trimester: Lay the Foundation

During the initial prenatal visit, do not wait until 24 weeks to introduce GDM. Embed the topic in the broader conversation about pregnancy nutrition and glucose metabolism. Use simple language: “Your body is working hard to support your baby. Sometimes the hormones of pregnancy make it harder to keep blood sugar in a healthy range. That is why we will check for gestational diabetes around your sixth month. It’s a routine test that helps us protect both of you.” This normalizes the test and reduces anxiety.

Also identify women at high risk and schedule early screening (at the first visit if they have BMI ≥ 30, prior GDM, or evidence of pre‑existing diabetes). Document the plan in the chart and give the patient a written reminder.

Second Trimester: Clear Communication Before the OGTT

At the 20‑week anatomy scan visit, briefly revisit GDM screening. Provide a handout (printed or digital) that explains:

Why the test is performed (early detection prevents complications)
How to prepare (fasting instructions, what to eat or not eat the night before)
What the beverage tastes like and strategies to minimize nausea (chill it, sip slowly, use a straw)
What happens if the result is abnormal (diagnostic OGTT, then nutrition counseling and monitoring)

Role‑play a positive frame: “This test is one of the most important things we can do to ensure a healthy baby. I have seen so many women who are glad they did it because it caught something early.” Avoid fear‑based messaging, which can backfire.

During the Screening Visit: Create a Supportive Environment

If the patient is present for the GCT in the office, the time spent while waiting for the blood draw is an opportunity for advocacy. Acknowledge the inconvenience: “I know this takes time out of your day, and I appreciate you doing it.” Offer a quiet room, a sip of water (if not fasting), and a distraction such as a short educational video about GDM. Use the moment to answer questions that the patient may have been hesitant to ask.

If the screening is performed at an outside lab, follow up proactively. Send a portal message or make a phone call to confirm the appointment and provide encouragement. Some practices use automated texts that include a link to a brief FAQ page. Every touchpoint reinforces the message that GDM screening matters.

When Screening Indicates GDM: Advocacy Continues

Receiving a GDM diagnosis can be overwhelming. The way the news is delivered influences the patient’s engagement with management. Use the following approach:

Start with empathy: “This diagnosis does not mean you did anything wrong. Many women develop GDM, and we have excellent treatments to keep you and your baby healthy.”
Provide a clear action plan: Refer to a registered dietitian or diabetes educator, prescribe a glucometer, and set up a follow‑up visit within two weeks. Write down the steps.
Normalize the use of medication: If lifestyle changes are insufficient, emphasize that insulin or metformin is safe and effective. Do not let the patient feel like a failure for needing medication.
Connect to peer support: Share local support groups or online communities (e.g., the GDM Support Network) where women share tips and encouragement.

A patient who feels supported at diagnosis is more likely to adhere to glucose monitoring and clinic visits—ultimately leading to better outcomes.

Provider-Level Systems to Improve Screening Rates

Individual advocacy is powerful, but system‑wide changes ensure that screening becomes automatic for every patient. Consider implementing the following in your practice:

Electronic Health Record (EHR) Reminders

Set up best‑practice alerts (BPAs) that fire at 24 weeks for patients who have not yet completed screening. Include a one‑click order for the GCT. BPAs have been shown to increase GDM screening rates by 15–20% in some health systems.

Standardized Screening Protocols

Adopt a single, consistent protocol (e.g., ACOG’s two‑step approach) and train all nursing and medical staff on it. Eliminate variation that can cause confusion or missed screenings. Post a visual algorithm in exam rooms.

Patient Education Materials in Multiple Languages

Create or curate handouts at a 5th‑grade reading level, translated into the languages commonly spoken in your community. Include pictures of the glucose drink, a food list for the preceding meal, and a timeline of steps. The ADA and ACOG offer downloadable materials.

Shared Decision-Making Tools

For women with high risk who need early screening, use a simple decision aid that presents the pros and cons of testing at different times. Research shows that shared decision‑making increases patient satisfaction and uptake of recommended tests.

Sample Practice Flow

Visit Week	Action
First prenatal (8–12 wks)	Assess risk factors; schedule early OGTT if high risk; provide GDM overview handout
20 weeks	Review GDM screening plan; address questions; send reminder for 24‑wk test
24–28 weeks	Perform GCT; if abnormal, complete diagnostic OGTT; follow‑up within 1 week
After diagnosis	Refer to dietitian; prescribe glucometer; schedule monthly visits

Overcoming Common Patient Concerns

Even with clear protocols, patients may resist screening. Below are three frequently raised objections and evidence‑based responses.

“I don’t want to drink that sweet liquid—it makes me sick.”

Acknowledge the concern: “Many women feel that way. Let me give you some tips: chill the drink first, drink it through a straw, and ask if you can have a small cracker afterward if you feel nauseous. If vomiting occurs within 30 minutes, we can repeat the test another day. The discomfort is temporary, but the information we get is invaluable.”

“I don’t have diabetes in my family, so I doubt I need this.”

Provide a simple physiology explanation: “Pregnancy hormones can interfere with insulin, even in women without any family history. That is why we recommend the test for everyone. I have seen many women with no risk factors develop GDM—and they are grateful we caught it early.”

“I don’t have time for another appointment.”

Offer flexible solutions: “We can schedule the GCT to coincide with your next prenatal visit, so you don’t have to come in extra. If you prefer a weekend lab, let us know. The 3‑hour diagnostic test can often be done at a lab near your work. We will help you find a time that works.”

The Role of Technology in Advocacy

Digital tools extend advocacy beyond the clinic walls. Patient portals can deliver automated reminders, educational videos, and secure messaging for questions. Telehealth follow‑ups after a GDM diagnosis allow more frequent touchpoints without added travel. Mobile apps such as MySugr or Glucose Buddy help women log blood sugars and share data with their care team. Recommending a reliable app during the screening discussion shows that you are thinking about her ongoing experience, not just checking a box.

For clinicians, continuous glucose monitors (CGMs) are increasingly used in GDM management, but they are not a substitute for the initial OGTT. Be prepared to explain that the diagnostic test remains the gold standard because it provides a standardized, reproducible measure of glucose tolerance.

Advocacy Beyond the Office Visit

Effective advocacy also involves speaking up at the practice, hospital, and policy levels. A clinician who believes in universal screening can:

Champion a quality improvement project that tracks GDM screening rates and identifies reasons for gaps.
Lead a continuing education session for colleagues on the latest evidence and communication techniques.
Collaborate with community health workers to reach women who may not access prenatal care until the third trimester.
Support policy initiatives that require insurance plans to cover screening without copays (as mandated by the Affordable Care Act for USPSTF‑recommended screenings, including GDM).

When providers become vocal advocates, they normalize GDM screening as a routine, non‑negotiable part of prenatal care—removing the stigma and confusion that still surround it.

Conclusion

Advocating for gestational diabetes screening during prenatal visits is not a one‑time conversation—it is a continuous process of education, reassurance, and system improvement. By understanding the barriers patients face, communicating clearly and empathetically, and embedding screening into practice workflows, clinicians can ensure that the vast majority of pregnant women receive this guideline‑recommended test.

The benefits are clear: lower rates of macrosomia, fewer birth injuries, reduced risk of preeclampsia, and a generation of women who are aware of their future diabetes risk. Each prenatal visit is an opportunity to make that difference. With the strategies outlined in this article, any provider can become a stronger advocate for GDM screening—one conversation at a time.